Vantage Biosciences Completes Enrollment in Phase 2 SeeClear Study of Oral Oruvestat in Non-Proliferative Diabetic Retinopathy

Vantage Biosciences completes enrollment in the Phase 2 SeeClear study of oral oruvestat in non-proliferative diabetic retinopathy.